InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Browse the detailed record of transactions filed by Didier Hoch, Président du Conseil d’administration d’OSE Immunotherapeutics. Director active across 2 companies, notably OSE Immunotherapeutics. In total, 5 reports have been published. Total volume traded: €68k. The latest transaction was disclosed on 19 September 2025 — Exercice. Regulator: AMF. All data is openly available.
Declarations5 total
€35,70390,000 shares@ €0.39670.023% mcap30.4% of flow
BSPCEEuronext Paris
2025DD1058931·
€22,05222,052 shares@ €1.000.18% mcap100.0% of flow
ActionEuronext Paris
2024DD1000137·
Ideal exit: 5 Jul 2025 (T+270)
022,052 shares0
ActionEuronext Paris
2024DD1000544·
Ideal exit: 5 Jul 2025 (T+270)
€35,80010,000 shares@ €3.5830.5% of flow
Option d'achatEuronext Paris
2024DD971951·
€45,8796,369 shares@ €7.20350.029% mcap39.1% of flow
ActionEuronext Paris
2024DD971114·
5 of 5 declarations
About Didier Hoch
Didier Hoch is a seasoned executive in the pharmaceutical and biotechnology sectors, with more than 25 years of experience in healthcare leadership. He held senior roles at Rhône-Poulenc Rorer and later Aventis, including Vice President for the Middle East and Africa. From 2000 to 2010, he served as President of Sanofi-Pasteur MSD, the vaccine joint venture between Sanofi and Merck. That role placed him at the center of industrial execution, regulatory complexity, and international vaccine strategy, and it helped establish his reputation in healthcare governance, commercial development, and cross-border leadership. Beyond operational management, Didier Hoch has also held influential positions in European vaccine and biotech industry organizations. He was Vice President and then President of Vaccine Europe from 2002 to 2010, and he chaired the Biotechnology Committee of LEEM from 2006 to 2012. These appointments reflect his ability to represent a sector, engage with public-health stakeholders, and contribute to broader industry policy discussions. In 2014, he co-founded and led Big Booster, a start-up accelerator, underscoring his interest in entrepreneurship and early-stage innovation. In listed companies, Didier Hoch has built a profile as a board leader in healthcare. He is Chairman of the Board of OSE Immunotherapeutics, where he was appointed in 2024. OSE is a biotechnology company focused on first-in-class immunotherapies in immuno-oncology and immuno-inflammation, and his appointment fits a governance model aimed at strategic continuity and growth execution. He has also held mandates at Pherecydes and Goliver Therapeutics. Overall, his profile combines pharmaceutical industry depth, boardroom experience, partnership-oriented thinking, and a strong understanding of value creation in publicly listed life-sciences companies.
